Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib

Table 7 Univariate analysis of time to progression using Kaplan-Meier method

Prognostic factors	TARE_alone (n = 63)				TARE_sorafenib (n = 81)
	n1	c1	HR (95%CI)	P value	n1	c1	HR (95%CI)	P value
ECOG2
0	32	13	0.57 (0.27-1.19)	0.131	40	8	1.96 (1.11-3.45)	0.018
1	28	13			40	16
BCLC stage3
B	26	9	0.62 (0.30-1.28)	0.193	16	5	1.02 (0.53-1.99)	0.947
C	31	14			65	19
Child-pugh class
A	57	24	0.35 (0.10-1.22)	0.083	78	23	0.75 (0.18-3.13)	0.694
B	6	3			3	1
AFP
< 400 ng/mL	54	22	0.73 (0.25-2.10)	0.556	52	15	0.78 (0.45-1.35)	0.378
≥ 400 ng/mL	9	5			29	9
Cirrhosis
Absence	15	6	1.08 (0.51-2.32)	0.835	29	7	1.39 (0.82-2.38)	0.222
Presence	48	21			52	17
Number of tumors
Single	12	6	0.71 (0.29-1.73)	0.449	9	5	0.59 (0.21-1.65)	0.308
Multiple	51	21			72	19
Lobar involvement
Unilobar	33	16	0.52 (0.27-1.04)	0.058	22	7	0.95 (0.52-1.74)	0.870
Bilobar	30	11			59	17
Infiltrative tumor4
Absence					58	15	1.14 (0.62-2.09)	0.673
Presence					23	9
MVI4
Absence					56	12	1.76 (0.92-3.35)	0.081
Presence					24	11
EHD4
Absence					60	23	0.37 (0.21-0.65)	< 0.001
Presence					21	1
IHT4
≤ 50%					37	15	0.54 (0.32-0.93)	0.024
> 50%					44	9

¹Total patients (n) and censored patients (c).

²ECOG 2 (n = 2 TARE_alone, n = 1 TARE_sorafenib) and ECOG 3 (n = 1 TARE_alone, n = 0 TARE_sorafenib) excluded.

³BCLC A (n = 5 TARE_alone, n = 0 TARE_sorafenib) and BCLC D (n = 1 TARE_alone, n = 0 TARE_sorafenib) excluded.

⁴Absent in all TARE_alone procedures according to institutional treatment algorithm.

Hazard ratios (HR) with Cox proportional hazard regression and P value with log-rank test. TARE: Transarterial radioembolization; ECOG: Eastern cooperative oncology group; BCLC: Barcelona clinic liver cancer; AFP: Alpha-fetoprotein; MVI: Macrovascular invasion; EHD: Extrahepatic disease; IHT: Intrahepatic tumor.